Status:
COMPLETED
Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen
Lead Sponsor:
Sun Yat-sen University
Conditions:
Polypoidal Choroidal Vasculopathy
Eligibility:
All Genders
40-99 years
Phase:
NA
Brief Summary
The aim of this study is to compare the outcomes of different treatment methods including photodynamic therapy (PDT), intravitreal ranibizumab injection (IVR) and combination therapy under the "1+PRN"...
Detailed Description
The optimal treatment for PCV is still under debate. Little knowledge is known about the treatment effect of "1+pro re nata(PRN)" treatment regimen for PCV. The aim of this study is to compare the out...
Eligibility Criteria
Inclusion
- active macula-involved polypoidal lesions evidenced by ICGA;
- greatest linear dimension of 5400 μm or less assessed by ICGA;
- follow-up of at least 12 months.
Exclusion
- any other ocular disease, such as ocular trauma, glaucoma, uveitis, diabetic retinopathy, angioid streaks, pathologic myopia, or presumed ocular histoplasmosis syndrome;
- any systemic contraindication to the PDT, IVR, sodium fluorescein, or indocyanine green dyes;
- any severe uncontrolled systemic disease, such as uncontrolled hypertention, coronary heart disease, liver failure, or kidney failure.
Key Trial Info
Start Date :
December 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 30 2015
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03459144
Start Date
December 1 2012
End Date
July 30 2015
Last Update
March 8 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, China, 510060